S8 Ep24: Jakubowiak Highlights PFS Benefit Seen With KRd Maintenance in Newly Diagnosed Multiple Myeloma
Dr Jakubowiak discusses interim findings from the ATLAS trial of KRd vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma, contextualizes these data within the broader post-transplant landscape, and previews the next steps for this research.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.